Showing results (351-360 of 5,165) with videos related to
Sort By:
Pageof 517
Current Oncology (Toronto, Ont.)|February 9, 2021
How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer PatientsXiaofu Zhu, Susan Dent, Lise Paquet, et al.Current Oncology (Toronto, Ont.)|January 27, 2021
Donor-Recipient Story in Allogeneic Hematopoietic Stem Cell TransplantationElena Kum, Gabriele Jagelaviciute, Edward Li, et al.Current Oncology (Toronto, Ont.)|February 24, 2021
Efficacy of 177Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry StudyGolmehr Sistani, Duncan E K Sutherland, Amol Mujoomdar, et al.Current Oncology (Toronto, Ont.)|February 11, 2021
The Quality of Online Information for an Uncommon Malignancy-Neuroendocrine Tumours (NETs)Safa Sohail, Victoria Zuk, Thorvardur Halfdanarson, et al.Current Oncology (Toronto, Ont.)|February 10, 2021
Gemcitabine-Containing Chemotherapy for the Treatment of Metastatic Myxofibrosarcoma Refractory to Doxorubicin: A Case SeriesArielle Elkrief, Suzanne Kazandjian, Thierry AlcindorCurrent Oncology (Toronto, Ont.)|September 25, 2019
Utility of a chemotherapy toxicity prediction tool for older patients in a community settingC Mariano, R Jamal, P Bains, et al.Current Oncology (Toronto, Ont.)|September 25, 2019
An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunctionC C Barron, M M Alhussein, U Kaur, et al.Current Oncology (Toronto, Ont.)|September 25, 2019
Resource use in the last three months of life by lung cancer patients in southern OntarioY Wang, A Van Dam, M Slaven, et al.Current Oncology (Toronto, Ont.)|September 25, 2019
Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphomaP Skrabek, S Assouline, A Christofides, et al.Current Oncology (Toronto, Ont.)|September 25, 2019
Exploring reasons for overuse of contralateral prophylactic mastectomy in CanadaJ E Squires, S N Simard, S Asad, et al.Pageof 517